Tactile Systems Technology reported a 5% increase in total revenue to $73.1 million for Q3 2024. The company saw improvements in profitability and authorized a share repurchase program of up to $30 million.
Total revenue increased 5% year-over-year to $73.1 million.
Lymphedema product revenue increased 4% over Q3 2023.
Airway clearance product revenue increased 10% over Q3 2023.
Ended Q3 2024 with $82.1 million in cash and cash equivalents.
The Company is updating its 2024 financial outlook and now expects full year 2024 total revenue in the range of $292 million to $295 million, representing growth of approximately 6% to 8% year-over-year, compared to total revenue of $274.4 million in 2023.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance